Pfizer Inc said on Tuesday it expects to generate US$15 billion (RM60.66 billion), or about a quarter of its total revenue this year, from sales of its Covid-19 vaccine co-developed with German partner BioNTech SE.

Sales from the vaccine - on track to be the drug maker's top product this year - could top US$15 billion if the company signs more supply contracts, it said.

Pfizer aims to make two billion doses of the Covid-19 vaccine in 2021. Pfizer Chief Executive Albert Bourla said in an interview that the company wanted to be conservative in its target and is working on numerous initiatives to exceed that output...